FindTrial
Sign In

Expression and Clinical Significance of TET1 in Plasma Exosomes of Colorectal Cancer Patients

Expression and Clinical Significance of TET1 in Plasma Exosomes of Colorectal Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116387
Enrollment
Unknown
Registered
2026-01-09
Start date
2026-01-09
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Interventions

Colorectal Cancer Group:none

Sponsors

Jiangwan Hospital of Hongkou District,Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Open to both men and women 2. Aged between 50 and 70 years 3. Confirmed diagnosis of colorectal cancer 4. Locally advanced, resectable

Exclusion criteria

Exclusion criteria: 1.Patients who have received preoperative neoadjuvant therapy. 2.Patients with advanced (stage III/IV), metastatic, or postoperatively recurrent colorectal cancer. 3.Patients with a history of other malignancies within the past 3 years.

Design outcomes

Primary

MeasureTime frame
The difference in TET1 expression levels in plasma exosomes between the colorectal cancer group and the healthy control group.;Immunohistochemistry results;—

Secondary

MeasureTime frame
Pathological diagnosis;—

Countries

China

Contacts

Public ContactShen,Zhiyong

Jiangwan Hospital of Hongkou District,Shanghai

shenzhiyong@jiangwanhosp.com+86 21 65422593

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026